Status: Recruitment ongoing, study in progress
Number of volunteers: 100 healthy volunteers
Length of study: June 2011 - end of study estimated in June 2012

A double-blinded, randomized phase IB trial aimed at studying the incidence of antigenic competition on the immunogenicity of Gag/Pol for HIV-1: a comparison between rAd5 gag/pol Env A/B/C and rAd5 gag/pol.

The Vaccine and Immunotherapy Center (VIC) has a large experience in testing of preventive vaccines against HIV.

This phase IB clinical trial is designed to evaluate the safety and to compare the immune response induced by vaccine-type adenovirus (rAd5), which affect about 50% of the Swiss population.

25 volunteers at low risk of HIV infection, aged 18-50 years, men (circumcised) and women, will be enrolled at the Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, for a period of 6 months. A total of 5 visits are scheduled including a full medical check-up, a single immunization visit and 3 follow-up visits with blood samples.

This clinical study is coordinated by the HIV Vaccine Trials Network (HVTN) and funded by the National Institutes of Health (NIH).

For further information on this study, please consult the information sheet (in French - 459 Ko) and contact us on 021 314 11 60.

Status: Study in progress
Number of volunteers: 80 healthy volunteers  at CHUV
Length of study: June 2009 - end of study October 2012
 

A phase IB clinical trial to evaluate the safety and immunogenicity of heterologous prime/boost vaccine regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in healthy, HIV-1 uninfected, Ad5 seronegative adult participants.

The aim of this phase IB clinical trial is to evaluate the safety of heterologous prime/boost vaccine regimens against HIV (NYVAC-B/rAd5 vs rAd5/NYVAC-B) in HIV-1 seronegative individuals and to compare the immune response induced by each of  those vaccination regimens.
In the rAd5/NYVAC-B regimen, 3 doses of rAd5 will be explored. The doses of NYVAC and rAd5, as well as the vaccination schedule, are based on data from previous pre-clinical and clinical trials.

80 healthy HIV seronegative volunteers, male or female, between 18 and 45 years old, will be enrolled at the Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, for 12 months. They will be randomized into one of the 4 groups outlined below, some of which will receive the vaccine regimen (75), and others the placebos only (5).

The study is funded by the Division of AIDS from the US National Institutes of Health and sponsored by the Eurovacc Foundation based in Lausanne, Switzerland. The HIV Vaccine Trials Network (HVTN) will coordinate this study.

End of recruitment.

Status: End of recruitment, study in progress
Number of volunteers: 70
Number of visits: 12
 

A Phase I  Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of BCG and AERAS-404 Administered as a Prime-Boost Regimen to HIV-Negative, TB-Negative, BCG-Naive Adults

BCG is currently the only licensed vaccine for the prevention of tuberculosis. The incomplete protection of this vaccine, especially in adults, makes it necessary to develop an effective booster in order to increase protection from TB disease.

The aim of this study is to assess the safety and the efficiency of BCG and a AERAS-404 two- or three-dose boost regimen administrated to healthy adults. 70 volunteers will be enrolled at the vaccine and immunotherapy Center, CHUV (Beaumont Hospital) for 10 months.

For this study, we are recruiting 18-50 years old women and men in good health and who didn’t get BCG vaccination.

For additional information, please contact us by phone 021 314 11 63.

Status: Study in progress
Number of volonteers: 48 (4 groups of 12 volunteers)
Number of visits: 13 or 15 (depending on the group number)
 

A Phase I randomized placebo-controlled study of a virosome-formulated anti-Candida vaccine (PEV7) administered by the vaginal or intramuscular route to healthy adult volunteers

The aim of PCAN001 study is to develop a preventive vaccine against the yeast Candida in order to treat and prevent the vaginal infections due to Candida albicans (vaginal mycosis).

Two objectives have been defined for this study: the first one is the evaluation of the safety and the tolerability of the vaccine and the second one is the determination of the immune response induced by this vaccine. Two types of immunisation ways will be tested and compared (intramuscular injections or intravaginal administration) over a period of 15 months.

For this study, we are recruiting 18-45 years old women in good health and under oral contraceptive (pill).

For additional information, please contact us by phone 021 314 11 63.